MRI在评估早期子宫内膜癌和宫颈癌保留生育功能治疗可行性中的作用
保留生育功能治疗(FST)已成为希望保留生育功能的育龄期妇科癌症患者管理的关键环节。欧洲妇科肿瘤学会、欧洲放射肿瘤学会、欧洲病理学会和欧洲人类生殖与胚胎学会等多家学会发布了关于早期妇科癌症(尤其是子宫内膜癌和宫颈癌)保留生育策略及治疗后监测的循证指南,强调MRI对初始患者选择和随访至关重要。放射科医生需熟悉FST准入标准及治疗前后的关键MRI表现,并在结构化MRI报告中全面沟通这些细节。
要点
- MRI是早期子宫内膜癌和宫颈癌保留生育功能治疗初始患者选择和随访的关键检查。
- 放射科医生需熟悉FST准入标准及治疗前后的关键MRI表现。
- 结构化MRI报告应全面沟通FST相关细节以支持多学科决策。
核心结论
- MRI是早期子宫内膜癌和宫颈癌保留生育功能治疗初始患者选择和随访的关键环节,放射科医生在多学科FST管理中发挥重要作用。
研究设计与样本
- 综述性文章,基于欧洲妇科肿瘤学会、欧洲放射肿瘤学会、欧洲病理学会和欧洲人类生殖与胚胎学会发布的循证指南,阐述MRI在FST评估中的作用。
诊断标准与关键数值
- 指南强调MRI对初始患者选择和随访至关重要。
- 需采用适当定制的盆腔MRI方案和清晰的MRI报告以进行准确分期、评估准入资格并确认FST初始及持续的可行性。
临床应用与阅片要点
- 放射科医生,尤其是妇科影像专科医生,应熟悉FST准入标准及治疗前后的关键MRI表现。
- 应在结构化MRI报告中全面沟通FST相关细节,以支持多学科FST管理。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Fertility-sparing treatment (FST) has become a key aspect of managing gynecologic cancers in reproductive-age patients who wish to preserve fertility. Several leading clinical societies, including the European Society of Gynecological Oncology, the European Society for Radiotherapy and Oncology, the European Society of Pathology, and the European Society of Human Reproduction and Embryology, have published evidence-based guidelines on fertility-sparing strategies and post-treatment surveillance of patients with early-stage gynecologic cancers, in particular endometrial and cervical cancers. These guidelines highlight MRI as essential to initial patient selection and follow-up. Properly tailored pelvic MRI protocols and clear MRI reports are key to performing accurate staging, assessing eligibility, and confirming the initial and ongoing feasibility of FST. Accordingly, radiologists, particularly those specializing in gynecologic imaging, play a critical role in the multidisciplinary approach to FST. They should be well-versed in FST eligibility criteria and key MRI findings before and after FST, ensuring these details are comprehensively communicated in structured MRI reports.
引用
- Lee M, Andrieu PIC, Nougaret S, et al. Role of MRI in Assessing the Feasibility of Fertility-Sparing Treatments for Early-Stage Endometrial and Cervical Cancers. AJR Am J Roentgenol. 2025. PMID: 39772587. doi:10.2214/AJR.24.32157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。